Cargando…
Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
SIMPLE SUMMARY: In the last decade, proteasome inhibitors have become a standard treatment for multiple myeloma. However, resistance to combined therapies remains a challenge due to the disease’s complex biology, crosstalk with the bone marrow microenvironment, and toxicities. To address this issue,...
Autores principales: | Mereu, Elisabetta, Abbo, Damiano, Paradzik, Tina, Cumerlato, Michela, Bandini, Cecilia, Labrador, Maria, Maccagno, Monica, Ronchetti, Domenica, Manicardi, Veronica, Neri, Antonino, Piva, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137151/ https://www.ncbi.nlm.nih.gov/pubmed/37190128 http://dx.doi.org/10.3390/cancers15082199 |
Ejemplares similares
-
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
por: Bandini, Cecilia, et al.
Publicado: (2023) -
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
por: Paradzik, Tina, et al.
Publicado: (2021) -
Augmented Production of Platelets From Cord Blood With Euchromatic Histone Lysine Methyltransferase Inhibition
por: Liu, Yiying, et al.
Publicado: (2022) -
Context-Dependent Requirement of Euchromatic Histone Methyltransferase Activity during Reprogramming to Pluripotency
por: Vidal, Simon E., et al.
Publicado: (2020) -
A sensitive homogeneous enzyme assay for euchromatic histone-lysine-N-methyltransferase 2 (G9a) based on terbium-to-quantum dot time-resolved FRET
por: Amjadi, Mohammad, et al.
Publicado: (2021)